Incidental finding of non-Hodgkin's lymphoma in a patient affected by castration-sensitive prostate cancer: A case report

Lymphoma

Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin

healthbook Times Oncology Hematology

Schmidt A

doi: 10.36000/hbT.OH.2020.06.025

Lung, Respiratory and Thoracic CancerFurther Publications

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

healthbook TIMES Oncology Hematology

Astaras C, Bettini A, Betticher D.C

doi: 10.36000/hbT.OH.2020.03.01

Genitourinary Cancer

Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

Lancet Oncol.

Duchesne GM, Woo HH, King M, Bowe SJ, Stockler MR, Ames A, D'Este C, Frydenberg M, Loblaw A, Malone S, Millar J, Tai KH, Turner S

doi: 10.1016/

Genitourinary Cancer

Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?

Alexander Meisela,b

doi: 10.36000/hbT.OH.2019.02.007

Lung, Respiratory and Thoracic CancerLymphoma

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Lancet Oncol.

Shaw AT, Kim TM, Crinò L, Gridelli C, Kiura K, Liu G, Novello S, Bearz A, Gautschi O, Mok T, Nishio M, Scagliotti G, Spigel DR, Deudon S, Zheng C, Pantano S, Urban P, Massacesi C, Viraswami-Appanna K, Felip E

doi: 10.1016/S1470-

Genitourinary Cancer

Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer

Prostate Cancer Prostatic Dis.

Nguyen PL, Martin NE, Choeurng V, Palmer-Aronsten B, Kolisnik T, Beard CJ, Orio PF, Nezolosky MD, Chen YW, Shin H, Davicioni E, Feng FY

doi: 10.1038/pcan.2016.58.

Genitourinary Cancer

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

Prostate.

Markowski MC, Shenderov E, Eisenberger MA, Kachhap S, Pardoll DM, Denmeade SR, Antonarakis ES

doi: 10.1002/pros.23955.

Genitourinary Cancer

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer

BJU Int.

Loeb S, Shin SS, Broyles DL, Wei JT, Sanda M, Klee G, Partin AW, Sokoll L, Chan DW, Bangma CH, van Schaik RHN, Slawin KM, Marks LS, Catalona WJ

doi: 10.1111/bju.13676.

Lymphoma

Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin's lymphoma

J Clin Pharm Ther.

Tran PN, Pinter-Brown LC

doi: 10.1111/jcpt.12572.

Related content

Hodgkin’s Lymphoma after Autologous Stem-Cell Transplantation: Effective Consolidation with Brentuximab Vedotin

Response to Osimertinib in a Patient With Non-Small Cell Lung Cancer and Two Uncommon EGFR mutations

Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Utilization of biopsy-based genomic classifier to predict distant metastasis after definitive radiation and short-course ADT for intermediate and high-risk prostate cancer

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer

Everolimus-induced nephrotic syndrome precipitated by interaction with voriconazole in a patient with Hodgkin's lymphoma